Stock Market Reviews

CV (CapsoVision, Inc.) News

Get the latest news, insights, and market updates on CV (CapsoVision, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Is CapsoVision (NASDAQ:CV) In A Good Position To Deliver On Growth Plans?
  There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
  Feb 16, 2026 - $CV
• Insider-Owned Growth Stocks Poised For Success In January 2026
  As U.S. markets navigate a landscape of rising Treasury yields and uncertainty surrounding Federal Reserve policies, investors are keenly observing insider activities as a potential indicator of confidence in company growth prospects. In this climate, stocks with high insider ownership may signal strong alignment between management and shareholders, which can be particularly appealing when market conditions are volatile.
  Jan 20, 2026 - $CV
• CapsoVision Submits FDA 510(k) for AI-Assisted Module in CapsoCam Plus
  CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.
  Jan 2, 2026 - $CV
• CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®
  Company Preparing to Commence Commercialization Following U.S. FDA 510(k) ClearanceSARATOGA, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam Plus®. The addition of this reading tool will improve the detection
  Dec 29, 2025 - $CV
• Insiders Favor These 3 Prominent Growth Companies
  As the U.S. stock market experiences fluctuations, with the Dow Jones reaching new highs before pulling back and tech stocks facing pressure due to AI bubble concerns, investors are keenly observing insider activity as a potential indicator of confidence in growth companies. In this context, high insider ownership can be seen as a vote of confidence from those closest to the business, suggesting that these insiders believe in their company's long-term prospects despite current market volatility.
  Dec 12, 2025 - $CV
• CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference
  Company to participate in 1:1 Investor Meetings on December 4, 2025SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will participate in the Benchmark 14th Annual Discov
  Nov 20, 2025 - $CV
• November 2025's High Growth Companies With Insider Influence
  As the U.S. market navigates the aftermath of a record government shutdown, with major indices like the Dow Jones and Nasdaq experiencing fluctuations, investors are paying close attention to sectors that can weather such uncertainties. In this context, growth companies with high insider ownership present an intriguing opportunity, as they often demonstrate strong alignment between management and shareholder interests—a critical factor in navigating volatile market conditions.
  Nov 13, 2025 - $CV
• CapsoVision Reports Third Quarter 2025 Financial Results
  SARATOGA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its third quarter ended September 30, 2025. Recent Highlights Third quarter 2025 revenue was $3.5 million, a 19% increase over the third quarter of 2024.New accounts grew 31% in the third quarter of 2025 over the comparable quarter in 2024.CapsoCam Plus® used b
  Nov 13, 2025 - $CV
• CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule
  Non-invasive capsule endoscopy system aims to enable earlier detection of pancreatic ductal adenocarcinoma - among the most fatal cancers worldwideSARATOGA, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device
  Nov 10, 2025 - $CV
• DraftKings, Flutter downgraded: Wall Street's top analyst calls
  DraftKings, Flutter downgraded: Wall Street's top analyst calls
  Nov 4, 2025 - $CV